Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 12/20 | 0.55 |
| ▸ | MAP4K1 | Q92918 | 6/20 | 0.53 |
| ▸ | ABL1 | P00519 | 8/20 | 0.51 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22362870 | 0.87 | LRRK2 (0.65) | LRRK2ABL1 | |
| SCHEMBL22362891 | 0.87 | LRRK2 (0.65) | LRRK2ABL1 | |
| SCHEMBL31119596 | 0.86 | MAP4K1 (0.56) | LRRK2MAP4K1ABL1RIPK1 | |
| SCHEMBL22363058 | 0.86 | MAP4K1 (0.56) | LRRK2MAP4K1ABL1RIPK1 | |
| SCHEMBL17066012 | 0.80 | LRRK2 (0.52) | LRRK2MAP4K1ABL1RIPK1 | |
| SCHEMBL17066016 | 0.79 | LRRK2 (0.53) | LRRK2MAP4K1ABL1 | |
| SCHEMBL22380022 | 0.79 | LRRK2 (0.58) | LRRK2MAP4K1ABL1 | |
| SCHEMBL17073819 | 0.78 | KDM5B (0.51) | LRRK2MAP4K1ABL1RIPK1 | |
| SCHEMBL22362816 | 0.77 | MAP4K1 (0.59) | LRRK2MAP4K1ABL1RIPK1 | |
| SCHEMBL17066094 | 0.77 | LRRK2 (0.51) | LRRK2MAP4K1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | 1ST Biotherapeutics, Inc. | 2020-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200270246-A1 | IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF NEURODEGENERATIVE DISORDERS | SMN1; SMN2, SNCA, HTT | LRRK2 82/4885MAP4K1 969/4885ABL1 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.